Format

Send to

Choose Destination
Mayo Clin Proc. 2001 May;76(5):476-87.

Retrospective cohort study of 148 patients with polyclonal gammopathy.

Author information

1
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

Abstract

OBJECTIVE:

To quantify clinical conditions and laboratory values associated with moderate to marked polyclonal gammopathy.

PATIENTS AND METHODS:

Patient characteristics, laboratory correlates, evolving disease states, and survival of all patients seen at the Mayo Clinic, Rochester, Minn, during 1991 with a polyclonal gamma globulin level of 3.0 g/dL or higher were reviewed in this retrospective cohort study.

RESULTS:

One hundred forty-eight patients were identified (median age, 58 years; 59% female). In 130 patients (88%), only 1 diagnosis was identified. Liver disease was the most common single disease association in 79 (61%) of 130 patients, followed by connective tissue diseases in 28 (22%), chronic infections in 8 (6%), hematologic disorders in 6 (5%), and nonhematologic malignancies in 4 (3%). No difference in gamma globulin levels existed between groups. With a median follow-up of 67 months, 90 (63%) of 143 patients for whom follow-up was available were alive. By multivariate analysis, age, albumin concentration, disease group, and platelet count were predictive of survival. No patient developed myeloma or a clonal plasmaproliferative disorder.

CONCLUSION:

Moderate to marked polyclonal gammopathy may reflect an underlying condition: liver disease, connective tissue disease, hematologic disorder, infection, or malignancy.

PMID:
11357794
DOI:
10.4065/76.5.476
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center